
Christopher Celano, MD
Associate Director,
Cardiac Psychiatry Research Program
Massachusetts General Hospital /
Harvard Medical School

Psychiatric Treatment of Cardiac Patients
Saturday, February 13, 2027
2:30 PM - 3:30 PM
Dr. Celano is a psychiatrist, Associate Director of the Cardiac Psychiatry Research Program at the Massachusetts General Hospital (MGH), and Associate Professor of Psychiatry at Harvard Medical School. Dr. Celano’s research focuses on the development and implementation of interventions to promote mental and physical health in individuals with cardiovascular disease.
He has served as the Principal Investigator of NIH- and foundation-funded studies to develop and implement health behavior interventions, including an ongoing R01-funded project to evaluate the efficacy of a psychological intervention to promote adherence in heart failure. He also has served as the Principal or Co-Investigator of multiple other projects related to health behavior promotion or the use of collaborative care to better identify and treat depression and anxiety disorders in individuals with heart disease. He has published over 120 articles, including over 70 original research articles and five meta-analyses.
Lecture Summary:
This presentation will examine the relationship between psychiatric symptoms and cardiovascular disease, with particular attention to depression, anxiety, and their impact on cardiovascular health outcomes. The session will review evidence-based psychopharmacologic treatment approaches for patients with cardiovascular disease, including first-line options for common mood and anxiety disorders. It will also address important cardiovascular side effects of psychiatric medications, such as QTc prolongation, and practical strategies for monitoring and reducing treatment-related risk.
Goals and Learning Objectives:
-
Attendees will be able to describe the relationships between depression, anxiety, and cardiovascular health outcomes.
-
Attendees will be able to describe the first-line treatments for depression and anxiety disorders in individuals with cardiovascular disease.
-
Attendees will be able to describe when and how to monitor for QTc prolongation and other cardiovascular side effects of psychiatric medications
Disclosures:
Other Financial Benefit : ICON Clinical Research Limited (for Novo Nordisk)
.png)